Bookmark and Share
imatinib (CID 5291) - Compound BioActivity Data
.
Filters: All Data » IC50      
Filter selected
BioActivity Outcomes:
Active(268)
 
 
Inconclusive(4)
 
 
Unspecified(472)
 
 
Top Targets:
7TM GPCR Srx(16)
 
 
 
7TM GPCR Srsx(15)
 
 
PTKc Abl(11)
 
 
PTKc Kit(8)
 
 
p450(7)
 
 
 
BioAssay Types:
Literature(257)
 
 
 
 
BioActivity Types:
IC50(744)
 
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 737    Data Row: 744   Total Pages: 15   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103245522]
IC50 0.0002Cytotoxicity against human EOL-1 cells after 72 hrs by alamar-blue cell viability assay [AID414750, Type: Literature]
View
2
[SID103245522]
IC50 0.0011Inhibition of wild type Bcr-Abl [AID463630, Type: Literature]
View
3
[SID103245522]
IC50 0.00605Antiproliferative activity against human imatinib-resistant K562 cells [AID590031, Type: Literature]
View
4
[SID103245522]
IC50 0.0108Inhibition of mouse recombinant N-terminal His6-tagged Abl by radiometric kinase assay [AID497611, Type: Literature]Tyrosine-protein kinase ABL1 [gi:59802613]
View
5
[SID103245522]
IC50 0.013Cytotoxicity against human TF1 cells expressing c-KIT mutation assessed as cell viability [AID649625, Type: Literature]
View
6
[SID103245522]
IC50 0.018Inhibition of PDGFRalpha by TR-FRET assay [AID407646, Type: Literature]
View
7
[SID103245522]
IC50 0.027Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-PDGFRbeta kinase assessed as proliferation after 48 hrs by MTT assay [AID512773, Type: Literature]
View
8
[SID103245522]
IC50 0.038Inhibition of v-Abl tyrosine kinase. [AID228823, Type: other]
View
9
[SID103245522]
IC50 0.038Inhibitory concentration against v-Abl tyrosine kinase [AID254706, Type: Literature]Tyrosine-protein kinase ABL1 [gi:85681908]
View
10
[SID103245522]
IC50 0.039Antiproliferative activity against PDGFRbeta transfected mouse BA/F3 cells [AID515836, Type: Literature]
View
11
[SID103245522]
IC50 0.039Inhibition of PDGFR [AID463623, Type: Literature]
View
12
[SID103245522]
IC50 0.04Inhibition of Abl tyrosine kinase [AID228828, Type: Literature]
View
13
[SID103245522]
IC50 0.04Inhibition of c-Abl [AID291752, Type: Literature]Tyrosine-protein kinase ABL1 [gi:85681908]
View
14
[SID103245522]
IC50 0.04Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis [AID721746, Type: Literature]Multidrug and toxin extrusion protein 1 [gi:74731723]
View
15
[SID103245522]
IC50 0.043Inhibition of autophosphorylation of DDR1 expressed in HEK293 cells by ELISA [AID515827, Type: Literature]
View
16
[SID103245522]
IC50 0.046Inhibition of SCF-induced phosphorylation of c-Kit in MO7e cells by TR-FRET assay [AID407624, Type: Literature]
View
17
[SID103245522]
IC50 0.049Cytotoxicity against human K562 cells after 72 hrs by alamar-blue cell viability assay [AID414726, Type: Literature]
View
18
[SID103245522]
IC50 0.05Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis [AID721747, Type: Literature]Multidrug and toxin extrusion protein 1 [gi:74731723]
View
19
[SID103245522]
IC50 0.05Inhibitory concentration against platelet-derived growth factor receptor [AID254803, Type: Literature]Platelet-derived growth factor receptor beta [gi:129890]
View
20
[SID103245522]
IC50 0.05Inhibitory concentration against platelet-derived growth factor receptor [AID254803, Type: Literature]Platelet-derived growth factor receptor alpha [gi:129892]
View
21
[SID103245522]
IC50 0.05Inhibition of the platelet-derived growth factor receptor. [AID161243, Type: other]
View
22
[SID103245522]
IC50 0.052Inhibition of c-Kit by TR-FRET assay [AID407623, Type: Literature]
View
23
[SID103245522]
IC50 0.052Inhibition of c-kit [AID343639, Type: Literature]
View
24
[SID103245522]
IC50 0.055Antiproliferative activity against mouse BA/F3 cells expressing Tel-SH2-KD assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay [AID512438, Type: Literature]
View
25
[SID103245522]
IC50 0.058Inhibition of c-kit [AID387174, Type: Literature]
View
26
[SID103245522]
IC50 0.058Inhibition of KIT [AID463624, Type: Literature]
View
27
[SID103245522]
IC50 0.06Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay [AID374947, Type: Literature]
View
28
[SID103245522]
IC50 0.072Inhibition of PDGFRbeta autophosphorylation in human A31 cells by ELISA [AID515828, Type: Literature]Platelet-derived growth factor receptor beta [gi:129890]
View
29
[SID103245522]
IC50 0.072Inhibition of human PDGFRalpha autophosphorylation in human A31 cells by ELISA [AID515829, Type: Literature]Platelet-derived growth factor receptor alpha [gi:129892]
View
30
[SID103245522]
IC50 0.07304SANGER: Inhibition of human LAMA-84 cell growth in a cell viability assay. [AID742302, Type: other]
View
31
[SID103245522]
IC50 0.088Antiproliferative activity against mouse BA/F3 cells expressing Tel-SH3-SH2-KD assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay [AID512745, Type: Literature]
View
32
[SID103245522]
IC50 0.0888SANGER: Inhibition of human EM-2 cell growth in a cell viability assay. [AID742144, Type: other]
View
33
[SID103245522]
IC50 0.08921SANGER: Inhibition of human MEG-01 cell growth in a cell viability assay. [AID742350, Type: other]
View
34
[SID103245522]
IC50 0.092Cytotoxicity against mouse BA/F3 cells transfected with wild type Bcr-Abl after 48 hrs by XTT assay [AID739102, Type: Literature]
View
35
[SID103245522]
IC50 0.096Inhibition of PDGFR alpha phosphorylation in G292 cell [AID262701, Type: Literature]Platelet-derived growth factor receptor alpha [gi:129892]
View
36
[SID103245522]
IC50 0.097Inhibition of human KIT autophosphorylation in human GIST882 cells by ELISA [AID515830, Type: Literature]Mast/stem cell growth factor receptor Kit [gi:125472]
View
37
[SID103245522]
IC50 0.098Inhibition of Abl by TR-FRET assay [AID407645, Type: Literature]
View
38
[SID103245522]
IC50 0.0982Inhibition of human recombinant wild type ABL1 expressed in insect cells after 30 mins by FRET assay [AID724981, Type: Literature]Tyrosine-protein kinase ABL1 [gi:85681908]
View
39
[SID103245522]
IC50 0.1Inhibitory concentration against c-Kit [AID254662, Type: Literature]Mast/stem cell growth factor receptor Kit [gi:125472]
View
40
[SID103245522]
IC50 0.1Inhibitory concentration against c-Kit wild type expressed in recombinant baculovirus [AID255004, Type: Literature]Mast/stem cell growth factor receptor Kit [gi:125472]
View
41
[SID103245522]
IC50 0.1Cytotoxicity against human K562 cells after 24 hrs by MTT assay [AID668693, Type: Literature]
View
42
[SID103245522]
IC50 0.1Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing wild type FLT3 assessed as cell viability after 72 hrs by luciferase assay [AID649619, Type: Literature]
View
43
[SID103245522]
IC50 0.108Antiproliferative activity against human GIST882 cells [AID515837, Type: Literature]
View
44
[SID103245522]
IC50 0.109Antiproliferative activity against human K562 expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay [AID512767, Type: Literature]
View
45
[SID103245522]
IC50 0.11Inhibition of Abl [AID343646, Type: Literature]
View
46
[SID103245522]
IC50 0.11Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay [AID709991, Type: Literature]
View
47
[SID103245522]
IC50 0.11Cytotoxic effect in K562 cells [AID94799, Type: Literature]
View
48
[SID103245522]
IC50 0.111Antiproliferative activity against human SUP-B15 expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay [AID512769, Type: Literature]
View
49
[SID103245522]
IC50 0.112Antiproliferative activity against mouse 32D cells transfected with p210 cells expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay [AID512764, Type: Literature]
View
50
[SID103245522]
IC50 0.112Inhibition of DDR [AID383339, Type: Literature]
View